<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Attorney At Law &#187; Opinion</title>
	<atom:link href="http://www.attorneyatlaw.com/category/opinion/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.attorneyatlaw.com</link>
	<description>Your source for legal news</description>
	<lastBuildDate>Mon, 19 Dec 2011 21:42:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Plastic Chemical BPA is “Of Some Concern” to Children, FDA Says (Finally)</title>
		<link>http://www.attorneyatlaw.com/2010/01/plastic-chemical-bpa-is-%e2%80%9cof-some-concern%e2%80%9d-to-children-fda-says-finally/</link>
		<comments>http://www.attorneyatlaw.com/2010/01/plastic-chemical-bpa-is-%e2%80%9cof-some-concern%e2%80%9d-to-children-fda-says-finally/#comments</comments>
		<pubDate>Fri, 15 Jan 2010 21:53:53 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bisphenol A (BPA)]]></category>
		<category><![CDATA[Opinion]]></category>
		<category><![CDATA[Toxic Exposure]]></category>

		<guid isPermaLink="false">http://www.attorneyatlaw.com/?p=3752</guid>
		<description><![CDATA[After months of waiting for the Food and Drug Administration to announce its new stance on the safety of the controversial plastic chemical bisphenol A (BPA), we now know the answer. Drum roll please. The FDA now says BPA should be “of some concern” for children and infants. The new stance on BPA represents a partial reversal for the agency, which has in the past contended that BPA – which is used to make infant bottles, sippy cups, and other &#8230;]]></description>
		<wfw:commentRss>http://www.attorneyatlaw.com/2010/01/plastic-chemical-bpa-is-%e2%80%9cof-some-concern%e2%80%9d-to-children-fda-says-finally/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Hasn’t Learned Its Lesson From Vioxx Fiasco</title>
		<link>http://www.attorneyatlaw.com/2009/12/fda-hasn%e2%80%99t-learned-its-lesson-from-vioxx-fiasco/</link>
		<comments>http://www.attorneyatlaw.com/2009/12/fda-hasn%e2%80%99t-learned-its-lesson-from-vioxx-fiasco/#comments</comments>
		<pubDate>Wed, 09 Dec 2009 16:37:52 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Dangerous Drugs]]></category>
		<category><![CDATA[Opinion]]></category>

		<guid isPermaLink="false">http://www.attorneyatlaw.com/?p=3368</guid>
		<description><![CDATA[Three years since major changes were recommended for how the Food and Drug Administration monitors drug safety after the Vioxx painkiller scandal, the federal agency has yet to implement most of the suggested improvements, according to Congressional investigators. Vioxx, the blockbuster pain drug that was FDA approved in 1999, was later pulled from the market in 2004 after it was associated with increased risks of heart attack and stroke. The Vioxx situation raised a red flag at the FDA, which &#8230;]]></description>
		<wfw:commentRss>http://www.attorneyatlaw.com/2009/12/fda-hasn%e2%80%99t-learned-its-lesson-from-vioxx-fiasco/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Should Big Pharma Really Be Your Facebook Friend?</title>
		<link>http://www.attorneyatlaw.com/2009/11/should-big-pharma-really-be-your-facebook-friend/</link>
		<comments>http://www.attorneyatlaw.com/2009/11/should-big-pharma-really-be-your-facebook-friend/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 18:37:09 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Opinion]]></category>

		<guid isPermaLink="false">http://www.attorneyatlaw.com/2009/11/should-big-pharma-really-be-your-facebook-friend/</guid>
		<description><![CDATA[Imagine among the slew of online updates you get about the daily comings and goings of your Facebook friends and tweets about the latest YouTube video of a cat playing drums, in comes a post about a new brand-name drug. That scenario may soon become a reality if drug industry officials get their way. Pharmaceutical companies are urging the Food and Drug Administration to develop new rules specifically for Internet promotion of drugs, which could open the door to much &#8230;]]></description>
		<wfw:commentRss>http://www.attorneyatlaw.com/2009/11/should-big-pharma-really-be-your-facebook-friend/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA is Slow to Act on Ineffective Drugs, Patients are Put at Risk</title>
		<link>http://www.attorneyatlaw.com/2009/10/fda-is-slow-to-act-on-ineffective-drugs-patients-are-put-at-risk/</link>
		<comments>http://www.attorneyatlaw.com/2009/10/fda-is-slow-to-act-on-ineffective-drugs-patients-are-put-at-risk/#comments</comments>
		<pubDate>Mon, 26 Oct 2009 16:25:42 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Opinion]]></category>

		<guid isPermaLink="false">http://www.attorneyatlaw.com/2009/10/fda-is-slow-to-act-on-ineffective-drugs-patients-are-put-at-risk/</guid>
		<description><![CDATA[When the Food and Drug Administration approves new drugs based on preliminary drug-company estimates of how effective the therapies will be, the agency most often fails to follow up on those claims to make sure they are accurate, according to a new government watchdog report. The result is that cancer drugs and other medications rushed through FDA approvals are allowed to remain in circulation despite the fact they do nothing to lengthen patients’ lives, relieve their pain, or treat their &#8230;]]></description>
		<wfw:commentRss>http://www.attorneyatlaw.com/2009/10/fda-is-slow-to-act-on-ineffective-drugs-patients-are-put-at-risk/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Do You Know What Merck Did Last Summer? Drug Company Paid Experts $3.7 Million to Promote Drugs</title>
		<link>http://www.attorneyatlaw.com/2009/10/do-you-know-what-merck-did-last-summer-drug-company-paid-experts-3-7-million-to-promote-drugs/</link>
		<comments>http://www.attorneyatlaw.com/2009/10/do-you-know-what-merck-did-last-summer-drug-company-paid-experts-3-7-million-to-promote-drugs/#comments</comments>
		<pubDate>Mon, 19 Oct 2009 22:13:21 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Opinion]]></category>

		<guid isPermaLink="false">http://www.attorneyatlaw.com/2009/10/do-you-know-what-merck-did-last-summer-drug-company-paid-experts-3-7-million-to-promote-drugs/</guid>
		<description><![CDATA[Drug maker Merck &#38; Co. admitted today that it paid $3.7 million over the summer to more than 1,000 doctors, nurses, and other medical professionals who gave speeches and did other work to promote the company’s medications. Pharmaceutical companies have been under increasing fire from critics over the common practice of keeping medical professionals on the payroll while failing to make public how much the experts were paid for their work. In response to the public outcry, Merck and other &#8230;]]></description>
		<wfw:commentRss>http://www.attorneyatlaw.com/2009/10/do-you-know-what-merck-did-last-summer-drug-company-paid-experts-3-7-million-to-promote-drugs/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Relenza Patient Death a Reason for Concern</title>
		<link>http://www.attorneyatlaw.com/2009/10/relenza-patient-death-a-reason-for-concern/</link>
		<comments>http://www.attorneyatlaw.com/2009/10/relenza-patient-death-a-reason-for-concern/#comments</comments>
		<pubDate>Mon, 12 Oct 2009 16:00:48 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Dangerous Drugs]]></category>
		<category><![CDATA[Opinion]]></category>

		<guid isPermaLink="false">http://www.attorneyatlaw.com/2009/10/relenza-patient-death-a-reason-for-concern/</guid>
		<description><![CDATA[The recent death of a patient who died after being given the influenza drug Relenza by doctors using a method that is not recommended by the Food and Drug Administration raises questions about patient safety. People who go to the doctor for medical treatment have a right to expect that their care will be administered properly, ethically, and in keeping with regulations for how drugs are used. When doctors take matters into their own hands and go against FDA regulations &#8230;]]></description>
		<wfw:commentRss>http://www.attorneyatlaw.com/2009/10/relenza-patient-death-a-reason-for-concern/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA&#8217;s Medical Device Recall System is Deeply Flawed, Experts Say</title>
		<link>http://www.attorneyatlaw.com/2009/10/fdas-medical-device-recall-system-is-deeply-flawed-experts-say/</link>
		<comments>http://www.attorneyatlaw.com/2009/10/fdas-medical-device-recall-system-is-deeply-flawed-experts-say/#comments</comments>
		<pubDate>Tue, 06 Oct 2009 16:16:19 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Medical Devices]]></category>
		<category><![CDATA[Opinion]]></category>

		<guid isPermaLink="false">http://www.attorneyatlaw.com/2009/10/fdas-medical-device-recall-system-is-deeply-flawed-experts-say/</guid>
		<description><![CDATA[The Food and Drug Administration’s system for recalling defective hip and knee replacements, surgical screws, and many other types of medical devices is seriously flawed, putting millions of patients at risk of life-threatening injuries, a leading medical industry watchdog foundation says. Failure to adequately track which all medical devices have been implanted in which patients and other glitches in the FDA’s monitoring system make ordering recalls of the products ineffective and leaves defectively dangerous devices in patients with no real &#8230;]]></description>
		<wfw:commentRss>http://www.attorneyatlaw.com/2009/10/fdas-medical-device-recall-system-is-deeply-flawed-experts-say/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>FDA&#8217;s Decision to Approve Use of Expired Tamiflu to Fight H1N1 Flu Virus Raises Red Flags</title>
		<link>http://www.attorneyatlaw.com/2009/10/fdas-decision-to-approve-use-of-expired-tamiflu-to-fight-h1n1-flu-virus-raises-red-flags/</link>
		<comments>http://www.attorneyatlaw.com/2009/10/fdas-decision-to-approve-use-of-expired-tamiflu-to-fight-h1n1-flu-virus-raises-red-flags/#comments</comments>
		<pubDate>Fri, 02 Oct 2009 20:50:18 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Opinion]]></category>

		<guid isPermaLink="false">http://www.attorneyatlaw.com/2009/10/fdas-decision-to-approve-use-of-expired-tamiflu-to-fight-h1n1-flu-virus-raises-red-flags/</guid>
		<description><![CDATA[The Food and Drug Administration today announced it will allow the use of certain lots of expired Tamiflu for Oral Suspension as part of the federal government’s response to the 2009 H1N1 Influenza public health emergency. In July, the FDA authorized the use of four lots of Tamiflu to be used as part of the government’s fight against H1N1, even though the lots had passed the expiration dates printed on their labels. Today, the FDA said it will allow another &#8230;]]></description>
		<wfw:commentRss>http://www.attorneyatlaw.com/2009/10/fdas-decision-to-approve-use-of-expired-tamiflu-to-fight-h1n1-flu-virus-raises-red-flags/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Most U.S. Parents Leery of H1N1 Vaccinations for Kids, Survey Says; Are Millions of Children Being Put at Risk?</title>
		<link>http://www.attorneyatlaw.com/2009/10/most-u-s-parents-leery-of-h1n1-vaccinations-for-kids-survey-says-are-millions-of-children-being-put-at-risk/</link>
		<comments>http://www.attorneyatlaw.com/2009/10/most-u-s-parents-leery-of-h1n1-vaccinations-for-kids-survey-says-are-millions-of-children-being-put-at-risk/#comments</comments>
		<pubDate>Thu, 01 Oct 2009 16:55:08 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Opinion]]></category>

		<guid isPermaLink="false">http://www.attorneyatlaw.com/2009/10/most-u-s-parents-leery-of-h1n1-vaccinations-for-kids-survey-says-are-millions-of-children-being-put-at-risk/</guid>
		<description><![CDATA[With health officials urging millions of Americans including young children to line up for a jab in the arm with a vaccine to prevent the H1N1 influenza virus, most parents are saying “not so fast.” A new study conducted by the publishers of Consumer Reports magazine found that nearly two-thirds of U.S. parents say they will either delay vaccinating their children against the H1N1 swine flu or will not let their children get the shots at all. The survey’s findings &#8230;]]></description>
		<wfw:commentRss>http://www.attorneyatlaw.com/2009/10/most-u-s-parents-leery-of-h1n1-vaccinations-for-kids-survey-says-are-millions-of-children-being-put-at-risk/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Bowed to Industry Pressure in Approving Knee Replacement Device, Official Admits</title>
		<link>http://www.attorneyatlaw.com/2009/09/fda-bowed-to-industry-pressure-in-approving-knee-replacement-device-official-admits/</link>
		<comments>http://www.attorneyatlaw.com/2009/09/fda-bowed-to-industry-pressure-in-approving-knee-replacement-device-official-admits/#comments</comments>
		<pubDate>Thu, 24 Sep 2009 20:26:42 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Medical Devices]]></category>
		<category><![CDATA[Opinion]]></category>

		<guid isPermaLink="false">http://www.attorneyatlaw.com/2009/09/fda-bowed-to-industry-pressure-in-approving-knee-replacement-device-official-admits/</guid>
		<description><![CDATA[The Food and Drug Administration threw out its own rule book and caved in to medical device company pressure in approving a knee-replacement device despite serious questions about its safety, the agency’s top lawyer said. The 2008 approval of ReGen Biologics’ Menaflex device, which is used for meniscus surgery, “constitutes a clear deviation from the principles of integrity used in this review and undermines the ability of the agency to counter the suggestion that lobbying on behalf of ReGen affected &#8230;]]></description>
		<wfw:commentRss>http://www.attorneyatlaw.com/2009/09/fda-bowed-to-industry-pressure-in-approving-knee-replacement-device-official-admits/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

